Results from Diamyd® Antigen-Specific Immunotherapy Trial in LADA published in scientific journal
Comprehensive 12-month results from the GADinLADA pilot-trial are now published in the peer-reviewed scientific journal Diabetes Obesity and Metabolism. The treatment with Diamyd[®] of individuals up to 70 years of age diagnosed with LADA, was safe and showed disease modifying potential. The top line results were first announced in July 2022.“The published data in this prominent journal brings to light the transformative potential of Diamyd[®] for LADA patients, aligning closely with the disease-modifying impact seen in type 1 diabetes, says Ulf Hannelius, President & CEO of Diamyd Medical.